Tang P - Search Results

1

Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience.

Tang P, Sun L, Uhlman MA, Polascik TJ, Freedland SJ, Moul JW. Tang P, et al. Cancer. 2010 Oct 15;116(20):4711-7. doi: 10.1002/cncr.25447. Cancer. 2010. PMID: 20589748 Free article.

2

Predicting non-organ-confined prostate cancer in men diagnosed after 2000.

Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW. Caire AA, et al. Among authors: tang p. Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51. doi: 10.1038/pcan.2010.15. Epub 2010 Jun 1. Prostate Cancer Prostatic Dis. 2010. PMID: 20514082

3

Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Tang P, et al. Urology. 2010 Nov;76(5):1058-62. doi: 10.1016/j.urology.2009.09.049. Epub 2009 Dec 29. Urology. 2010. PMID: 20035982

4

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW. Tang P, et al. J Urol. 2010 Mar;183(3):946-50. doi: 10.1016/j.juro.2009.11.021. Epub 2010 Jan 18. J Urol. 2010. PMID: 20083275

5

Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW. Tang P, et al. BJU Int. 2011 Jul;108(1):44-8. doi: 10.1111/j.1464-410X.2010.09812.x. Epub 2010 Nov 2. BJU Int. 2011. PMID: 21050357

6

Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences.

Tang P, Du W, Xie K, Fu J, Chen H, Yang W, Moul JW. Tang P, et al. Prostate. 2012 Feb 1;72(2):173-80. doi: 10.1002/pros.21418. Epub 2011 May 2. Prostate. 2012. PMID: 21538426

7

Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.

Qi P, Tsivian M, Abern MR, Bañez LL, Tang P, Moul JW, Polascik TJ. Qi P, et al. Among authors: tang p. Urol Oncol. 2013 Nov;31(8):1527-32. doi: 10.1016/j.urolonc.2012.06.003. Epub 2012 Jul 12. Urol Oncol. 2013. PMID: 22795501

8

Prostate volume as an independent predictor of prostate cancer in men with PSA of 10-50 ng ml(-1).

Tang P, Jin XL, Uhlman M, Lin YR, Deng XR, Wang B, Xie KJ. Tang P, et al. Asian J Androl. 2013 May;15(3):409-12. doi: 10.1038/aja.2013.11. Epub 2013 Apr 8. Asian J Androl. 2013. PMID: 23564045 Free PMC article.

9

Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.

Moul JW, Tang P, Sun L. Moul JW, et al. Among authors: tang p. Eur Urol. 2010 Mar;57(3):452. doi: 10.1016/j.eururo.2009.03.024. Epub 2009 Mar 13. Eur Urol. 2010. PMID: 19303696 No abstract available.

10

Risk stratification in the hormonal treatment of patients with prostate cancer.

Uhlman MA, Moul JW, Tang P, Stackhouse DA, Sun L. Uhlman MA, et al. Among authors: tang p. Ther Adv Med Oncol. 2009 Sep;1(2):79-94. doi: 10.1177/1758834009340164. Ther Adv Med Oncol. 2009. PMID: 21789114 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,337 results

Search Page

Filters